S&P 500   5,249.49 (+0.02%)
DOW   39,753.43 (-0.02%)
QQQ   444.26 (-0.13%)
AAPL   171.28 (-1.17%)
MSFT   420.11 (-0.31%)
META   485.84 (-1.62%)
GOOGL   150.77 (-0.07%)
AMZN   180.11 (+0.16%)
TSLA   177.57 (-1.26%)
NVDA   906.73 (+0.47%)
NIO   4.57 (-2.14%)
AMD   180.65 (+0.59%)
BABA   72.45 (+1.20%)
T   17.64 (+0.51%)
F   13.17 (+0.84%)
MU   117.93 (-1.02%)
CGC   9.77 (+2.30%)
GE   175.17 (-2.75%)
DIS   122.63 (+1.36%)
AMC   3.68 (-15.21%)
PFE   28.00 (+0.79%)
PYPL   67.18 (+0.92%)
XOM   115.86 (+0.77%)
S&P 500   5,249.49 (+0.02%)
DOW   39,753.43 (-0.02%)
QQQ   444.26 (-0.13%)
AAPL   171.28 (-1.17%)
MSFT   420.11 (-0.31%)
META   485.84 (-1.62%)
GOOGL   150.77 (-0.07%)
AMZN   180.11 (+0.16%)
TSLA   177.57 (-1.26%)
NVDA   906.73 (+0.47%)
NIO   4.57 (-2.14%)
AMD   180.65 (+0.59%)
BABA   72.45 (+1.20%)
T   17.64 (+0.51%)
F   13.17 (+0.84%)
MU   117.93 (-1.02%)
CGC   9.77 (+2.30%)
GE   175.17 (-2.75%)
DIS   122.63 (+1.36%)
AMC   3.68 (-15.21%)
PFE   28.00 (+0.79%)
PYPL   67.18 (+0.92%)
XOM   115.86 (+0.77%)
S&P 500   5,249.49 (+0.02%)
DOW   39,753.43 (-0.02%)
QQQ   444.26 (-0.13%)
AAPL   171.28 (-1.17%)
MSFT   420.11 (-0.31%)
META   485.84 (-1.62%)
GOOGL   150.77 (-0.07%)
AMZN   180.11 (+0.16%)
TSLA   177.57 (-1.26%)
NVDA   906.73 (+0.47%)
NIO   4.57 (-2.14%)
AMD   180.65 (+0.59%)
BABA   72.45 (+1.20%)
T   17.64 (+0.51%)
F   13.17 (+0.84%)
MU   117.93 (-1.02%)
CGC   9.77 (+2.30%)
GE   175.17 (-2.75%)
DIS   122.63 (+1.36%)
AMC   3.68 (-15.21%)
PFE   28.00 (+0.79%)
PYPL   67.18 (+0.92%)
XOM   115.86 (+0.77%)
S&P 500   5,249.49 (+0.02%)
DOW   39,753.43 (-0.02%)
QQQ   444.26 (-0.13%)
AAPL   171.28 (-1.17%)
MSFT   420.11 (-0.31%)
META   485.84 (-1.62%)
GOOGL   150.77 (-0.07%)
AMZN   180.11 (+0.16%)
TSLA   177.57 (-1.26%)
NVDA   906.73 (+0.47%)
NIO   4.57 (-2.14%)
AMD   180.65 (+0.59%)
BABA   72.45 (+1.20%)
T   17.64 (+0.51%)
F   13.17 (+0.84%)
MU   117.93 (-1.02%)
CGC   9.77 (+2.30%)
GE   175.17 (-2.75%)
DIS   122.63 (+1.36%)
AMC   3.68 (-15.21%)
PFE   28.00 (+0.79%)
PYPL   67.18 (+0.92%)
XOM   115.86 (+0.77%)
NYSE:ENFN

Enfusion (ENFN) Stock Price, News & Analysis

$9.26
+0.03 (+0.33%)
(As of 01:05 PM ET)
Today's Range
$9.22
$9.35
50-Day Range
$7.78
$9.57
52-Week Range
$7.37
$11.56
Volume
98,404 shs
Average Volume
408,379 shs
Market Capitalization
$1.19 billion
P/E Ratio
115.76
Dividend Yield
N/A
Price Target
$9.33

Enfusion MarketRank™ Stock Analysis

Analyst Rating
Reduce
1.67 Rating Score
Upside/​Downside
0.7% Upside
$9.33 Price Target
Short Interest
Bearish
6.71% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.04mentions of Enfusion in the last 14 days
Based on 4 Articles This Week
Insider Trading
Selling Shares
$54,849 Sold Last Quarter
Proj. Earnings Growth
142.86%
From $0.07 to $0.17 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.06 out of 5 stars

Computer And Technology Sector

494th out of 587 stocks

Prepackaged Software Industry

179th out of 198 stocks

ENFN stock logo

About Enfusion Stock (NYSE:ENFN)

Enfusion, Inc. provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides portfolio management system, which generates a real-time investment book of record that consists of valuation and risk tools that allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and order and execution management system that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines. It also offers accounting/general ledger system, a real-time accounting book of record for chief financial officers, chief operating officers, accountants, and operations teams; Enfusion analytics system, which enables CIOs, portfolio managers, traders, and analysts to analyze portfolios through time horizons and automate customized visualized reports for internal and external stakeholders; and technology-powered and managed services. The company was founded in 1997 and is headquartered in Chicago, Illinois.

ENFN Stock Price History

ENFN Stock News Headlines

Top Project Outperforms BTC in 2023…
According to a recently published report… One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen. And now, this crypto coin is set to soar in the parabolic bull run projected in 2024.
Analysts Set Enfusion, Inc. (NYSE:ENFN) PT at $9.33
Stifel Nicolaus Keeps Their Buy Rating on Enfusion (ENFN)
Top Project Outperforms BTC in 2023…
According to a recently published report… One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen. And now, this crypto coin is set to soar in the parabolic bull run projected in 2024.
William Blair Reaffirms Their Buy Rating on Enfusion (ENFN)
Earnings Outlook For Enfusion
Goldman Sachs Downgrades Enfusion (ENFN)
Enfusion to Host Investor Day on March 19, 2024
Enfusion downgraded to Underweight on client risks at JPMorgan
JP Morgan Downgrades Enfusion: Here's What You Need To Know
See More Headlines
Receive ENFN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Enfusion and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
3/28/2024
Next Earnings (Estimated)
5/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Industry
Prepackaged software
Sub-Industry
N/A
Fax
N/A
Employees
1,102
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$9.33
High Stock Price Target
$11.00
Low Stock Price Target
$8.00
Potential Upside/Downside
+1.2%
Consensus Rating
Reduce
Rating Score (0-4)
1.67
Research Coverage
6 Analysts

Profitability

Net Income
$6.03 million
Pretax Margin
6.58%

Debt

Sales & Book Value

Annual Sales
$174.54 million
Cash Flow
$0.15 per share
Book Value
$0.61 per share

Miscellaneous

Free Float
77,892,000
Market Cap
$1.18 billion
Optionable
Optionable
Beta
0.99
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

  • Mr. Oleg Movchan (Age 49)
    CEO & Director
    Comp: $876.34k
  • Mr. Bradley Herring (Age 53)
    Chief Financial Officer
    Comp: $267.05k
  • Ms. Bronwen Bastone (Age 51)
    Chief People Officer
    Comp: $566.25k
  • Mr. Stephen Malherbe
    Managing Partner
  • Mr. Neal Pawar
    Chief Operating Officer
  • Ms. Valeria Gutowski (Age 42)
    Chief Accounting Officer
  • Mr. Ignatius Tochukwu Njoku
    Head of Investor Relations
  • Matt Campobasso
    General Counsel
  • Mr. Joseph Defeo
    Global Head of Managed Services Production
  • Mr. Jeff Young
    Head of Implementation

ENFN Stock Analysis - Frequently Asked Questions

Should I buy or sell Enfusion stock right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Enfusion in the last year. There are currently 3 sell ratings, 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "reduce" ENFN shares.
View ENFN analyst ratings
or view top-rated stocks.

What is Enfusion's stock price target for 2024?

6 brokerages have issued 1 year price targets for Enfusion's shares. Their ENFN share price targets range from $8.00 to $11.00. On average, they anticipate the company's share price to reach $9.33 in the next twelve months. This suggests a possible upside of 0.7% from the stock's current price.
View analysts price targets for ENFN
or view top-rated stocks among Wall Street analysts.

How have ENFN shares performed in 2024?

Enfusion's stock was trading at $9.70 at the start of the year. Since then, ENFN shares have decreased by 4.4% and is now trading at $9.27.
View the best growth stocks for 2024 here
.

Are investors shorting Enfusion?

Enfusion saw a increase in short interest during the month of March. As of March 15th, there was short interest totaling 3,020,000 shares, an increase of 80.8% from the February 29th total of 1,670,000 shares. Based on an average daily volume of 395,300 shares, the short-interest ratio is currently 7.6 days. Approximately 6.7% of the shares of the company are sold short.
View Enfusion's Short Interest
.

When is Enfusion's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our ENFN earnings forecast
.

What guidance has Enfusion issued on next quarter's earnings?

Enfusion updated its FY 2024 earnings guidance on Tuesday, March, 12th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $200.0 million-$210.0 million, compared to the consensus revenue estimate of $202.3 million.

When did Enfusion IPO?

Enfusion (ENFN) raised $300 million in an initial public offering on Thursday, October 21st 2021. The company issued 18,750,000 shares at a price of $15.00-$17.00 per share.

Who are Enfusion's major shareholders?

Enfusion's stock is owned by a number of institutional and retail investors. Top institutional investors include Brown Capital Management LLC (9.27%), Vanguard Group Inc. (2.83%), Vanguard Group Inc. (2.83%), Wellington Management Group LLP (0.38%), Northern Trust Corp (0.27%) and Charles Schwab Investment Management Inc. (0.23%). Insiders that own company stock include Bradley Herring, Bronwen Bastone, Dan Groman, Deirdre Somers, Hillhouse Investment Managemen, Matthew Campobasso, Oleg Movchan, Roy Luo, Stephen Malherbe, Tarek Hammoud and Valeria Gutowski.
View institutional ownership trends
.

How do I buy shares of Enfusion?

Shares of ENFN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSE:ENFN) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners